536565-BOM

Novelix Pharmaceuticals Ltd.

BSE: 536565

Sector: Consumer Services

Industry Group: Retailing

Industry: Pharmacy Retail

67.00+0.5 (+0.74%)

17 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

30.4 / 100

Value Score

18.0 / 100

Price Momentum Score

76.3 / 100

QVM Score

29.9 / 100

Key Metrics

Market Cap

190.75

P/E (TTM)

74.61

P/B

4.10

P/S (TTM)

1.44

EV/EBITDA

52.49

CAPE (5Y)

ROE (TTM)

7.99

ROCE (TTM)

9.87

ROA (TTM)

4.27

Avg 3Y ROE

2.94

Earnings 3Y CAGR

Sales 3Y CAGR

355.00

Sales 5Y CAGR

70.28

Debt/Equity

0.09

Consensus TP

Strong Buy %

Promoter Holding

50.57

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Novelix Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 76.3 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

76.3 / 100

Strong revenue growth and above median growth of market

The company delivered strong revenue growth of 330.7% for 12-month ended 31 Mar 2026 and the growth was 320.25 percentage points higher than median growth of market

What is Sales growth (1Y)?

Median: 10.45

Value 330.7

-7635.64179204992

Strong EPS growth and above median growth of market

The company delivered strong EPS growth of 1244.44% for 12-month ended 31 Mar 2026 and the growth was 1239.1 percentage points higher than median growth of market

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.09 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.09 in the last 1 year

What is Debt to Equity?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to market median P/E

PE TTM of 74.61 indicates that the stock is expensive on a standalone basis and is at a 220.63% premium to market median P/E

What is P/E Ratio?

Median: 23.27

Value 74.61

-2948.5670376.2

Company's earnings are of low quality

Earnings quality score of 4.7 indicates that the company's earnings are of low quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

4.7 / 100

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Low ROE but improving trend

The company reported low ROE of 7.99% for 12-month ended 31 Mar 2026 but ROE improved by 730 bps from 1 year ago

What is ROE (FY)?

Low operating margin but improving trend

The company reported low operating margin of 2.55% for 12-month ended 31 Mar 2026 but operating margin improved by 220 bps from 1 year ago

What is Operating profit margin?

Financial Snapshot

See detailed analysis

Multi-year trends for Novelix Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Novelix Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Novelix Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	64.19	64.19	64.19	64.19	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.54	66.56	66.56	66.56	52.75	53.33	51.98	49.43	50.57
Indian Promoter	64.19	64.19	64.19	64.19	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.92	66.54	66.56	66.56	66.56	52.75	53.33	51.98	49.43	50.57
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	35.81	35.81	35.81	35.81	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.08	33.46	33.44	33.44	33.44	47.25	46.67	48.02	50.57	49.43
Bodies Corporate	-	-	14.28	14.28	14.28	14.28	14.28	14.33	14.28	9.65	9.65	9.65	9.75	9.84	9.84	9.85	8.30	10.28	11.64	11.71	11.71	8.84	6.15	4.12	3.09	2.81
Others (incl. Retail) No. of shareholders	35.81 2,162	35.81 2,155	21.53 2,129	21.53 2,152	18.80 2,182	18.80 2,332	18.80 2,360	18.75 2,324	18.80 2,401	23.43 2,404	23.43 2,400	23.43 2,402	23.33 2,384	23.24 2,361	23.24 2,359	23.23 2,589	24.78 2,604	23.18 2,544	21.80 2,505	21.73 2,474	21.73 2,456	38.41 2,383	40.52 2,674	43.90 2,968	47.48 2,949	46.62 3,090

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Novelix Pharmaceuticals Ltd. shares as reported to NSE and BSE.

No bulk, block or insider trade data available.

Corporate Actions

History of Novelix Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 0.30/share
Record date: 18th Aug 2012Ex-date: 16th Aug 2012
Announced on: 23rd Jul 2012
Dividend₹ 0.30/share
Record date: 24th Sep 2011Ex-date: 22nd Sep 2011
Announced on: 22nd Aug 2011
Others
Ex-date: 4th Oct 2010Announced on: 30th Jul 2010
BOD 30 July 2010. Nominal value changes from INR 1 to INR 10.
Dividend₹ 0.03/share
Record date: 24th Aug 2010Ex-date: 23rd Aug 2010
Announced on: 28th Jul 2010
Stock Split1 : 10
Ex-date: 15th Oct 2009Announced on: 25th Jul 2009
Nominal value change from Rs 10 each to Rs 1 each.

Company Profile

Overview of Novelix Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Companys segments include Pharma Business, Investment is Shares, Trading i...

Key personnel

Ms. Bhoomika Choudhary

Chief Financial Officer

Ms. Nishita Kalantri

Compliance Officer, Company Secretary

Shri. Arun Kumar BhangadiaD

Chairman of the Board, Managing Director

Mr. Venkateshwarlu PulluruD

Whole-time director

Ms. Sridevi BelideD

Additional Non-Executive Non-Independent Director

Shri. Arvind Kumar Devansh BhangadiaD

Non-Executive Director

Mr. Gattu Gnana PrakashD

Additional Non-Executive Non-Independent Director

Mr. Sagar Rajendra KarwaD

Additional Independent Director

View all

Incorporated on

13 Dec 1994

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

27 Sep 1995

Free Float

96,93,142

Website

https://www.trimurthidrugs.com/

Phone no.

+914024757370

Address

5-8-354, Office no-1106, Ratna block, Raghav Ratna towers Chirag Ali late, Abids, HYDERABAD, 500001, India

Frequently Asked Questions

What is the current share price of Novelix Pharmaceuticals Ltd.?

The current share price of Novelix Pharmaceuticals Ltd. is ₹ 67.00 as of 17 Jul 2026.

What is the market capitalisation of Novelix Pharmaceuticals Ltd.?

The market capitalisation of Novelix Pharmaceuticals Ltd. stands at ₹ 190.75 Cr.

What is the PE ratio of Novelix Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Novelix Pharmaceuticals Ltd. is 74.61 as of the latest trailing twelve months data.

What is the ROE and ROCE of Novelix Pharmaceuticals Ltd.?

Novelix Pharmaceuticals Ltd. has a Return on Equity (ROE) of 7.99% and a Return on Capital Employed (ROCE) of 9.87% as per the latest financial reports.

What is the 52-week high and low of Novelix Pharmaceuticals Ltd.?

The 52-week high of Novelix Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Novelix Pharmaceuticals Ltd.?

The dividend yield of Novelix Pharmaceuticals Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Novelix Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 46.62% of Novelix Pharmaceuticals Ltd. shares.

What sector does Novelix Pharmaceuticals Ltd. belong to?

Novelix Pharmaceuticals Ltd. operates in the Consumer Services sector.

What is the beta of Novelix Pharmaceuticals Ltd.?

The beta of Novelix Pharmaceuticals Ltd. is 0.55, indicating its price volatility relative to the broader market. Over the past 1 year, Novelix Pharmaceuticals Ltd. has delivered an absolute return of 44.12%.

What is the RSI of Novelix Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Novelix Pharmaceuticals Ltd. is 42.06, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Novelix Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Novelix Pharmaceuticals Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions